GLP-1 Cross-Sector Digest
TL;DR
The scientific narrative pivoted hard this cycle: at EASD in Milan, both majors declared the amylin era open, with Lilly's EloraTZP posting 23.3% weight loss and Novo countering with CagriSema "food noise" brain data. Meanwhile Foundayo's scripts inflected (+21% in a week), Novo paid up to $2.6B for a preclinical weekly pill, and the category's marketing language quietly shifted from "patients" to "customers."
The amylin era officially arrived — and Lilly owns the efficacy end of it
The next generation of obesity drugs is now defined by amylin-based combinations, and EASD 2026 delivered the data that splits the field in two. Lilly's EloraTZP (eloralintide + tirzepatide) hit 23.3% mean weight loss at 48 weeks — versus 14.8% for tirzepatide 15 mg alone — with a Phase 3 launch planned before year-end (EASD 2026 nextgen data+1). Novo's answer was CagriSema at 22.4% versus placebo plus fMRI data showing the drug "changed brain responses to food, potentially making food fixations less intense."
"The amylins still cause some nausea, but it's at less than half the rate of what we generally see in GLP-1 trials… So I am personally very sanguine about amylins." — EASD 2026 nextgen data
+1 (Source: TIME, Oct. 1, 2026)
The frontier is bifurcating: maximum-efficacy combos (EloraTZP, CagriSema) versus tolerability-first amylin monotherapy — Zealand's petrelintide (10% weight loss in The Lancet, side effects near placebo), AbbVie's ABBV-295 with 8% weight loss on monthly dosing. Leerink's $23B 2035 forecast for eloralintide tells you where the sell-side thinks the value sits. This extends last cycle's Viking maintenance thesis: persistence and tolerability, not raw weight loss, are the differentiators (EASD 2026 nextgen data+1).
What to watch: EloraTZP's Phase 3 initiation — now an open thread — is the lead indicator for whether Lilly's amylin-combo franchise cements the cross-trial narrative.
Foundayo's inflection is real, and Lilly is buying it with price and ads
The oral race has entered a new phase: Foundayo's weekly scripts surged ~21% to 64,268 while Novo's Wegovy pill has been stuck between 181K and 184K for five weeks, and Lilly now holds 26% of the oral obesity market (Oral GLP-1 race). Three levers drove it: the Martha Stewart DTC ad in late August, the Medicare Bridge's $50 copay, and a Sept. 1 self-pay price cut to $149 for starting doses.
"We're seeing early signs of growth in Q3 for Foundayo." — Oral GLP-1 race
(Source: Fierce Pharma Oral GLP-1 Tracker, Oct. 2, 2026)
The context check matters: Foundayo took 25 weeks to reach what the Wegovy pill did in 7, so this is an inflection, not a reversal — but Ricks' claim of 1 in 3 new oral starts "growing week over week" shows the trajectory. The pills continue to broaden the class rather than split it, with tirzepatide at ~57% of the total GLP-1 market.
What to watch: Whether Foundayo holds above 60K weekly as the $149 promo laps — and whether Novo answers with pricing before the January 2027 list-price cuts.
Novo is buying optionality it couldn't build
Novo's post-CMD spending spree culminated in a $2.6B milestone-laden deal with China's Hengrui for HRS-1596, a once-weekly oral GLP-1/GIP dual agonist meant to compete with Zepbound (Novo strategic reset). The catch: the drug has "yet to be tested in humans."
"HRS-1596 may not address those concerns." — Novo strategic reset
(Source: BioPharma Dive, Sept. 29, 2026)
This is the fourth recent pipeline transaction (Kallyope, Orbis, Vivtex, plus the UBT251 license), and Leerink flagged that Kailera — whose pipeline was built from Hengrui-licensed assets — "might have had right of first refusal." A "Phase 1 ready" asset does nothing for the 2027–2029 P&L while the January price-cut wall and the CagriSema FDA decision (~Nov 15) loom; the spree reads as management acknowledging the next-gen gap is real.
What to watch: Whether Morningstar's top-ranked zenagamtide (2029 est.) gets its Phase 3 T2D start — the only next-gen asset that could restore credibility on Novo's own pipeline.
The category is rebranding itself as lifestyle — and that cuts both ways
Novo is now marketing Wegovy with slogans like "Live lighter" and "Summer Glow Up," calling users "customers" rather than "patients," and relabeling the drug from "anti-obesity medicine" to "weight loss" drug (GLP-1 lifestyle marketing shift).
"Once promoted as tools to address obesity as a medical issue, GLP-1 drugs are increasingly being seen — and marketed — as a way to look and feel better generally." — GLP-1 lifestyle marketing shift
(Source: STAT, Sept. 28, 2026)
The commercial logic is clear — >80% of Wegovy pill new prescriptions come from people new to GLP-1 therapy, and cosmetically-motivated self-pay users are exactly who $149 Foundayo targets. But the tension is real: the more the category markets itself as cosmetics-adjacent, the more ammunition payers have to treat it as discretionary.
What to watch: Whether employer coverage pullbacks (the Cigna move) accelerate as lifestyle framing gives payers cover.
The legal overhangs are in limbo — both at once
Two courtroom binaries sit unresolved. In MDL-3094, Judge Marston's Daubert hearing on general causation closed September 18 with no ruling — roughly 4,022 gastroparesis cases ride on whether plaintiffs' experts can testify at all (GLP-1 MDL litigation). Meanwhile Novo's Lanham Act suit over Lilly's comparative ads — which pit Zepbound against Wegovy while omitting the 7.2 mg dose — got its injunction hearing August 27 with no ruling yet, against stakes of ~700 million impressions and $67.8M in Q2 Zepbound TV spend (GLP-1 MDL litigation
). Neither has a date certain, which is itself the story: the litigation discount on both stocks can't resolve until the court moves.
What to watch: The Daubert opinion — the single biggest binary event for the litigation overhang.
What surprised us
- Lilly cut price to buy the inflection, not just defend share. The $149 promo was framed as an "elasticity experiment" — meaning Lilly is actively testing the demand curve in real time, a luxury Novo's flat Wegovy pill scripts don't afford it.
- Novo's best EASD data wasn't the weight loss. The real-world shot-to-pill switch study (an additional 4.1% weight loss after switching to the pill) and Wegovy normalizing liver fat in 9 of 10 adults are quiet market-expansion stories buried under the CagriSema headline.
- The Hengrui deal may have stepped on Kailera's toes. If Kailera held a right of first refusal on HRS-1596, Novo paid up to $2.6B for an asset whose clean ownership isn't settled — preclinical risk on top of deal risk.
- "Customers" is a load-bearing word. The patient-to-customer shift is a leading indicator of the payer tension that could undermine the entire coverage-expansion thesis.